ResearchMoz

Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description

GBI Research
Published Date » 2014-02-06
No. Of Pages » 101
   
 GBI Research has released its pharma report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth”. The systemic psoriasis market is forecast to grow substantially over the forecast period from $5.0 billion in 2013 to $10.4 billion in 2020, across the eight major markets. This growth will be driven by a rising treatment population and the continued uptake of biologics. Biologics will continue to drive market growth despite leading brands Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) losing patent protection in most of the major markets over the forecast period. Although the market will suffer revenue losses as a result of sales erosion from biosimilar...
Table of Content

1 Table of Contents 1
1.1 List of Tables 4
1.2 List of Figures 5

2 Executive Summary 6
2.1 Changes to Treatment Usage Patterns will Drive Market Growth 6
2.2 Biologics to Gain Prominence as Promising Novel Drugs Enter the Market 6

3 Introduction 7
3.1 Overview 7
3.2 Epidemiology 8
3.3 Etiology, Co-morbidities and Risk Factors 9
3.3.1 Genetics 9
3.3.2 Psoriatic Arthritis 9
3.3.3 Mental Health Disorders 10
3.3.4 Metabolic Syndrome, Smoking, Diet and Alcohol Consumption 10
3.3.5 Infections 10
3.3.6 Köebner Phenomenon 11
3.3.7 Other Immune-mediated Diseases 11
3.4 Pathophysiology 11
3.5 Diagnosis 12
3.6 Treatment Options 12
3.6.1 Pharmacological Therapies 13
3.6.2 Non-pharmacological Therapies 14
3.6.3 Combination and Rotational Therapies 14
3.6.4 Quality of Life Assessments 15
3.7 Summary 15
3.8 GBI Research Report Guidance 15

4 Marketed Products 16
4.1 Overview 16
4.2 Methotrexate-based Products 16
4.3 Sandimmune/Neoral (cyclosporine/modified cyclosporine) – Novartis 17
4.4 Soriatane (acitretin) – Steifel Laboratories 18
4.5 Fumaderm (dimethyl fumarate and ethyl fumarate) – Biogen Idec 19
4.6 Humira (adalimumab) – Abbvie Inc. 20
4.7 Enbrel (etanercept) – Amgen Inc. 21
4.8 Remicade (infliximab) – Janssen Biotech 22
4.9 Stelara (ustekinumab) – Janssen Biotech 23
4.10 Marketed Products Heat Map 24

5 Pipeline 27
5.1 Overview 27
5.2 Pipeline Size and Distribution by Phase, Molecule Type and Program Type 28
5.3 Pipeline Distribution by Molecular Target 30
5.4 Clinical Trial Landscape 32
5.4.1 Clinical Trial Duration 32
5.4.2 Clinical Trial Size 36
5.5 Clinical trial failure rates 40
5.6 Primary and Secondary Endpoints 41
5.7 Summary of Psoriasis Clinical Trials 43
5.8 Promising pipeline molecules 43
5.8.1 Ixekizumab – Eli Lilly 43
5.8.2 Xeljanz (tofacitinib) – Pfizer 44
5.8.3 Brodalumab – Amgen 45
5.8.4 Apremilast – Celgene 46
5.8.5 Secukinumab – Alcon 47
5.9 Heat Map for Pipeline Products 47

6 Market Forecast to 2020 52
6.1 Overview 52
6.2 Global Market 52
6.3 North America 55
6.3.1 Treatment Usage Patterns 55
6.3.2 Annual Cost of Treatment 56
6.3.3 Market Size 58
6.4 Top Five EU Markets 59
6.4.1 Treatment Usage Patterns 59
6.4.2 Annual Cost of Treatment 60
6.4.3 Market Size 61
6.5 Japan 62
6.5.1 Treatment Usage Patterns 62
6.5.2 Annual Cost of Treatment 63
6.5.3 Market Size 64
6.6 Drivers and Barriers for the Systemic Psoriasis Therapeutics Market 65
6.6.1 Drivers 65
6.6.2 Barriers 65

7 Co-development and Licensing deals 67
7.1 Co-development Deals 67
7.1.1 Abbvie Enters into Co-development Agreement with Biotest for Tregalizumab 70
7.1.2 Lycera Enters into Research Agreement with Merck & Co. 70
7.1.3 LEO Pharma Enters into Research Agreement with 4SC Discovery for Inflammatory Skin Diseases 70
7.1.4 Amgen Enters into Co-Development Agreement with AstraZeneca for Five Human Monoclonal Antibodies Including Brodalumab 70
7.2 Licensing Deals 72
7.2.1 Leo Pharma Enters into Licensing Agreement with Virobay for Psoriasis Drug 75
7.2.2 Foamix Enters into Licensing Agreement with Dr. Reddy's Labs 75
7.2.3 Cipher Pharma Enters into Licensing Agreement with IBSA Institut Biochimique for Betesil Patch 75
7.2.4 Phenex Pharma Enters into Licensing Agreement with Janssen Biotech for Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program 75

8 Appendix 76
8.1 All Pipeline Drugs by Phase 76
8.1.1 Discovery 76
8.1.2 Preclinical 78
8.1.3 Phase I 82
8.1.4 Phase II 84
8.1.5 Phase III 86
8.1.6 Undisclosed 87
8.2 Market Forecasts to 2020 87
8.2.1 Major Developed Markets 87
8.2.2 US 88
8.2.3 UK 88
8.2.4 France 89
8.2.5 Germany 89
8.2.6 Italy 90
8.2.7 Spain 90
8.2.8 Japan 91
8.2.9 Canada 91
8.3 Abbreviations 92
8.4 References 93
8.5 References for Heat Maps 98
8.5.1 Marketed Products 98
8.5.2 Pipeline products 98
8.6 Methodology 100
8.6.1 Secondary Research 100
8.6.2 Therapeutic Landscape 100
8.7 Contact Us 100
8.8 Disclaimer 101

List of Tables


Table 1: Type of Psoriasis 8
Table 2: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Discovery, 2014 76
Table 3: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Preclinical/IND/CTA-filed, 2014 78
Table 4: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Phase I, 2014 82
Table 5: Systemic Psoriasis Therapeutics Market, Global, Phase II, Discovery, 2014 84
Table 6: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Phase III/Pre-registration, 2014 86
Table 7: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Undisclosed, 2014 87
Table 8: Systemic Psoriasis Market Forecast, Global, 2013–2020 87
Table 9: Systemic Psoriasis Market Forecast, US, 2013–2020 88
Table 10: Systemic Psoriasis Market Forecast, UK, 2013–2020 88
Table 11: Systemic Psoriasis Market Forecast, France, 2013–2020 89
Table 12: Systemic Psoriasis Market Forecast, Germany, 2013–2020 89
Table 13: Systemic Psoriasis Market Forecast, Italy, 2013–2020 90
Table 14: Systemic Psoriasis Market Forecast, Spain, 2013–2020 90
Table 15: Systemic Psoriasis Market Forecast, Japan, 2013–2020 91
Table 16: Systemic Psoriasis Market Forecast, Canada, 2013–2020 91
Table 17: Breakdown of ‘Others’ Category 99
Table 18: Breakdown of ‘Combination’ Category 99

List of Figures


Figure 1: Systemic Psoriasis Therapeutics Market, Global, Market Size, 2013–2020 6
Figure 2: Psoriasis Treatment Algorithms 13
Figure 3: Heat Map for Marketed Products 24
Figure 4: Heat Map for Marketed Products (continued) 25
Figure 5: Psoriasis Therapeutics Market, Global, Pipeline, 2013 28
Figure 6: Psoriasis Therapeutics Market, Global, Pipeline by Molecular Target, 2013 30
Figure 7: Psoriasis Therapeutics Market, Global, Pipeline by Molecular Target, 2013 31
Figure 8: Psoriasis Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Molecule Type, (months) 2006–2012 33
Figure 9: Psoriasis Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Molecular Target, (months) 2006–2012 35
Figure 10: Psoriasis Therapeutics Market, Global, Pipeline, Clinical Trial Size by Molecule Type, (participants) 2006–2012 37
Figure 11: Psoriasis Therapeutics Market, Global, Pipeline, Clinical Trial Size by Molecular Target, (participants), 2006–2012 39
Figure 12: Psoriasis Therapeutics Market, Global, Clinical Trial Failure Rate, (%), 2006–2013 40
Figure 13: Psoriasis Therapeutics Market, Global, Frequency of Primary Endpoints Measured in Clinical Trials, (%), 2006–2012 41
Figure 14: Psoriasis Therapeutics Market, Global, Frequency of Secondary Endpoints Measured in Clinical Trials, (%), 2006–2012 42
Figure 15: Heat Map for Pipeline Products 48
Figure 16:Heat Map for Marketed Products 49
Figure 17:Heat Map for Marketed Products (continued) 50
Figure 18: Systemic Psoriasis Therapeutics Market, Global, Treatment Patterns (million), 2013–2020 52
Figure 19: Systemic Psoriasis Therapeutics Market, Global, Market Size ($bn), 2013–2020 54
Figure 20: Systemic Psoriasis Therapeutics Market, North America, Treatment Patterns, 2013–2020 55
Figure 21: Systemic Psoriasis Therapeutics Market, North America, Annual Cost of Treatment ($), 2013–2020 56
Figure 22: Systemic Psoriasis Therapeutics Market, North America, Market Size, 2013–2020 58
Figure 23: Systemic Psoriasis Therapeutics Market, Top Five EU Countries, Treatment Patterns (‘000), 2013–2020 59
Figure 24: Systemic Psoriasis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2013–2020 60
Figure 25: Systemic Psoriasis Therapeutics Market, Top Five EU Countries, Market Size ($m), 2013–2020 61
Figure 26: Systemic Psoriasis Therapeutics Market, Japan, Treatment Patterns (‘000), 2013–2020 62
Figure 27: Systemic Psoriasis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2013–2020 63
Figure 28: Systemic Psoriasis Therapeutics Market, Japan, Market Size ($m), 2013–2020 64
Figure 29: Psoriasis Therapeutics Market, Global, Co-development Deals, 2006–2013 67
Figure 30: Psoriasis Therapeutics Market, Global, Co-development Deals by Phase of Development, Molecule Type and Aggregate Deal Value ($m), 2006–2013 69
Figure 31: Psoriasis Therapeutics Market, Global, Licensing Deals, 2006–2013 72
Figure 32: Psoriasis Therapeutics Market, Licensing Deals by Phase, Molecule Type and Aggregate Deal Value ($m), 2006–2013 73

Upcoming Reports:

Greece: pistachios market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the pistachios market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the pistachios market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the...
Poland: floor mats market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the floor mats market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the floor mats market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the...
Advanced (3D/4D) Visualization Systems Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
By - Transparency Market Research
Technological innovations have made computing of multiple probe signals possible across various imaging modalities. The market for advanced (3D/4D) visualization systems has seen proliferation from the advances in the field of computer hardware and software, in addition to advancements in the field of AV technology (3D) and PACS module. A significant improvement in the area of advanced visualization has been the move from a thick client to a thin client server and to cloud technology. Advanced (3D/4D) visualization systems are increasingly finding demand in various...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Ireland Residential Construction Starts Slow
Mar 2, 2015  
Experts said that the Irish residential construction industry has had a dramatically slow start to their activities in early 2015. The slump follows a substantial rise in the planning activities for residential applications and constructions projects from 2014. The current data that has been taken from Link2Plans, an independent planning research company, displays a 12% increase in...
India Construction Sector Rises 15 Per Cent
Mar 2, 2015  
Construction and infrastructure shares of all related companies gained steam in trading after an announcement by the government that they had increased spending in the sector. The Indian government will raise their investments in the infrastructure by nearly Rs 700 billion. They have also made plans to initiate a national infrastructure investment fund. They also plan to create road...
Kansas Streetcar Construction on Schedule for Early 2016
Mar 2, 2015  
The downtown streetcar construction for Kansas City is almost 50 per cent complete and officials say that the construction should be complete by this fall. Post construction, the streetcars that will be used will then undergo months of testing before they are approved for passenger usage. They are scheduled to be in full operation in the early months of 2016. Tom Gerend, the...
Renewed PPP Model Emphasizes on the Bottom of the Pyramid of Agricultural Sector
Mar 2, 2015  
India’s budget is very comprehensive as it seeks to obtain a thorough balance between sustainable growth and inclusiveness. It focuses on the savings in the middle class as well as emphasizes on the core of the pyramid.  India has used a pragmatic approach in this. It is used to stabilize the economy and maintain the inflation under check. While the emphasis on Make in India...
The Leading Five Things to Observe in Tallahassee Food and Beverages
Mar 2, 2015  
The five things to watch in Florida’s Capitol is the date of Florida’s 2016 presidential primary. The panel considers complying with the national political party rules as the date for March 15 is set. This could play a bigger role with the expected candidacies of the U.S. and Governor of the state.  The stores in poor areas could reap a food bazaar with a few grocery...